According to the Zhitong Finance App, Lianya Pharmaceutical (301569.SZ) issued an initial public offering of shares and a prospectus of intent to list on GEM. The number of shares in this public offering was 13,37395.63 million shares, accounting for 15% of the total share capital after issuance. The initial inquiry date is September 22, 2026, and the subscription date is September 28, 2026. The number of initial strategic placements issued in this offering was 40,1218.68 million shares, accounting for approximately 30.00% of the current offering. Among them, the issuer's senior management and core employees participating in the special asset management plan set up in this strategic placement are expected to be no more than 10.00% of the number of subscriptions, that is, no more than 13.3739.56 million shares, and the subscription amount is no more than 31.3 million yuan; other investors participating in the strategic placement have a total subscription amount of no more than 30 million yuan; the initial follow-up amount of the sponsor's related subsidiaries is approximately 5.00% of the current issuance volume, or 6.686.978 million shares.

According to the Zhitong Finance App, Lianya Pharmaceutical (301569.SZ) issued an initial public offering of shares and a prospectus of intent to list on GEM. The number of shares in this public offering was 13,37395.63 million shares, accounting for 15% of the total share capital after issuance. The initial inquiry date is September 22, 2026, and the subscription date is September 28, 2026. The number of initial strategic placements issued in this offering was 40,1218.68 million shares, accounting for approximately 30.00% of the current offering. Among them, the issuer's senior management and core employees participating in the special asset management plan set up in this strategic placement are expected to be no more than 10.00% of the number of subscriptions, that is, no more than 13.3739.56 million shares, and the subscription amount is no more than 31.3 million yuan; other investors participating in the strategic placement have a total subscription amount of no more than 30 million yuan; the initial follow-up amount of the sponsor's related subsidiaries is approximately 5.00% of the current issuance volume, or 6.686.978 million shares.